Roche Sees Signs Esbriet May Extend Lives in Deadly Lung Ailment

  • Esbriet cuts risk of death by 38% after 2 years of treatment
  • Drug may earn Roche more than CHF2b in sales by 2020

Roche Holding AG said there’s evidence its Esbriet treatment for a rare and deadly lung disease can extend lives.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.